BML (4694) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 FY2025 rose 6.8% year-over-year to ¥38,026 million, driven by new customer acquisition and pricing strategies.

• Operating profit increased 10.1% year-over-year to ¥2,804 million, and profit attributable to owners of parent grew 9.1% to ¥1,862 million.

• The business environment remained challenging due to rising costs and competition, but no reduction in medical service fees occurred.

Financial highlights

• Gross profit for Q1 FY2025 was ¥12,516 million, up from ¥11,956 million in Q1 FY2024.

• Ordinary profit reached ¥2,904 million, a 9.6% increase year-over-year.

• Basic earnings per share rose to ¥47.75 from ¥43.81 year-over-year.

• Comprehensive income for Q1 FY2025 was ¥1,862 million, up from ¥1,719 million in Q1 FY2024.

Outlook and guidance

• Full-year FY2025 net sales forecast is ¥148,000 million, up 3.4% year-over-year.

• Operating profit is projected at ¥9,000 million (down 3.9%), and profit attributable to owners of parent at ¥6,000 million (down 4.2%).

• No changes to previously announced forecasts.